Objective Otitis media (OM) is one of the most frequent diseases in childhood and the most common indication for the prescription of antibiotics. Recurrent OM affects up to 40% of children and may persist for weeks to months causing symptoms ranging from hearing loss and tinnitus to anorexia or conjunctivitis.The main causative agents of OM are the bacterial pathogens Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. Acute otitis media (AOM) is characterised by the presence of middle ear effusion accompanied by the rapid onset of signs of inflammation such as otalgia, otorrhea or fever. As AOM is very painful, it results very often in antibiotic treatment. Yet solid evidence is lacking that it alters the course of OM disease in children. A prophylactic vaccine would be able to reduce the misery of children by preventing the occurrence of OM altogether. The advances in genomic research have enabled a comprehensive search for antigens and vaccine candidates. Intercell has successfully applied the novel antigenome technology to identify protective antigens from S. pneumoniae. Together with complementary proteomic approaches we now aim to identify novel vaccine candidates for the two pathogens M. catarrhalis and H. influenzae, which can function as targets for protective immunity preventing OM.This study aims to select candidate antigens for evaluation in clinical trials for the prevention of OM. The consortium partners maintain the highest quality of research and technology in their respective field, among them proven and renowned experts of OM research, proteomic and MS techniques and of vaccine development. This work will generate valuable intellectual property, but it will further broaden the expertise of all partners and the understanding of the underlying mechanisms of OM disease. Fields of science natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenzamedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programme(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Topic(s) LSH-2005-1.2.5-4 - Innovative research in post-genomics, which has high potential for application Call for proposal FP6-2005-LIFESCIHEALTH-7 See other projects for this call Funding Scheme STREP - Specific Targeted Research Project Coordinator INTERCELL AG Address Campus vienna biocenter 6 Vienna Austria See on map Links Website Opens in new window EU contribution € 0,00 Participants (6) Sort alphabetically Sort by EU Contribution Expand all Collapse all 2ND DEPARTMENT OF PEDIATRICS, SEMMELWEIS UNIVERSITY Hungary EU contribution € 0,00 Address Tüzoltó 7-9 Budapest See on map Links Website Opens in new window AGOWA GESELLSCHAFT FÜR MOLEKULARBIOLOGISCHE TECHNOLOGIE MBH Germany EU contribution € 0,00 Address Glienicker weg 185 Berlin See on map Links Website Opens in new window ERASMUS UNIVERSITY MEDICAL CENTRE ROTTERDAM Netherlands EU contribution € 0,00 Address Dr. molewaterplein 46-60 Rotterdam See on map Links Website Opens in new window KAROLINSKA INSTITUTET Sweden EU contribution € 0,00 Address Nobels väg 16 Solna See on map Links Website Opens in new window STICHTING KATHOLIEKE UNIVERSITEIT, MORE PARTICULARY THE RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTRE Netherlands EU contribution € 0,00 Address Geert grooteplein 10 Nijmegen See on map Links Website Opens in new window UNIVERSITAET GRAZ Austria EU contribution € 0,00 Address Universitaetsplatz 3 Graz See on map Links Website Opens in new window
